AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The National Eligibility-Entrance Test Super Speciality (NEET-SS) 2024 finally took place on March 29-30, 2025, following ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...

After lots of controversy regarding the conduction of the exam, the National Eligibility-Entrance Test Super Speciality (NEET ...

AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, ...

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) saw a significant drop in short interest in March. As of March ...

Deficiency of the pancreatic progenitor cell differentiation and proliferation factor gene was identified as a risk factor ...